SEC Form 4 · accession 0001193125-26-309047
Kalaris Therapeutics, Inc. · KLRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Liisa Ann Bayko
Officer — Chief Financial Officer
Period of report
Jul 20, 2026
Accepted (ET)
Jul 20, 2026 · 5:04 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001754068
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $4.00 | Jul 20, 2026 | A | 220,000 | A | — | Jul 19, 2036 | Common Stock | 220,000 | 220,000 | D |
Explanation of responses
- F1The option was granted on July 20, 2026. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on July 20, 2027 and the remainder vesting in equal monthly installments thereafter, subject to continuous service.